In vivo imaging of mGlu5 receptor expression in humans with Fragile X Syndrome towards development of a potential biomarker

[1]  Lauren E. Ethridge,et al.  Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial , 2021, Nature Medicine.

[2]  James Robert Brašić,et al.  Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Idiopathic Autism Spectrum Disorder and Fragile X Syndrome: A Pilot Study , 2021, International journal of molecular sciences.

[3]  James Robert Brašić,et al.  Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome , 2020, Brain sciences.

[4]  Kevin Sharp,et al.  A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments , 2020, Brain sciences.

[5]  Kelli C. Dominick,et al.  Developmental studies in fragile X syndrome , 2020, Journal of Neurodevelopmental Disorders.

[6]  James Robert Brašić,et al.  The Urgent Need for Molecular Imaging to Confirm Target Engagement for Clinical Trials of Fragile X Syndrome and Other Subtypes of Autism Spectrum Disorder , 2019, Archives of Neuroscience.

[7]  R. Hagerman,et al.  New Targeted Treatments for Fragile X Syndrome , 2019, Current Pediatric Reviews.

[8]  C. González-Billault,et al.  Structural and Functional Abnormalities in the Olfactory System of Fragile X Syndrome Models , 2019, Front. Mol. Neurosci..

[9]  L. Schmitt,et al.  Executive Function in Fragile X Syndrome: A Systematic Review , 2019, Brain sciences.

[10]  E. Berry-Kravis,et al.  Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective , 2018, Brain sciences.

[11]  Mark F. Bear,et al.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome , 2017, Nature Reviews Drug Discovery.

[12]  F. Battaglia,et al.  Impaired hippocampal representation of place in the Fmr1-knockout mouse model of fragile X syndrome , 2017, Scientific Reports.

[13]  A. Reiss,et al.  Updated report on tools to measure outcomes of clinical trials in fragile X syndrome , 2017, Journal of Neurodevelopmental Disorders.

[14]  J. Sweeney,et al.  Fragile X targeted pharmacotherapy: lessons learned and future directions , 2017, Journal of Neurodevelopmental Disorders.

[15]  D. Budimirovic,et al.  Fragile X Syndrome: Lessons Learned from the Most Translated Neurodevelopmental Disorder in Clinical Trials , 2017, Translational neuroscience.

[16]  Xinyu Zhao,et al.  MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome , 2016, Science Translational Medicine.

[17]  Jill L Silverman,et al.  Modeling fragile X syndrome in the Fmr1 knockout mouse. , 2014, Intractable & rare diseases research.

[18]  Kevin T. Chen,et al.  An SPM8-Based Approach for Attenuation Correction Combining Segmentation and Nonrigid Template Formation: Application to Simultaneous PET/MR Brain Imaging , 2014, The Journal of Nuclear Medicine.

[19]  Dalyir I. Pretto,et al.  Clinical and molecular implications of mosaicism in FMR1 full mutations , 2014, Front. Genet..

[20]  Allan L Reiss,et al.  Identifying large-scale brain networks in fragile X syndrome. , 2013, JAMA psychiatry.

[21]  Talakad G. Lohith,et al.  Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome? , 2013, Molecular Autism.

[22]  Jenna M. Sullivan,et al.  Kinetic Analysis of the Metabotropic Glutamate Subtype 5 Tracer [18F]FPEB in Bolus and Bolus-Plus-Constant-Infusion Studies in Humans , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  James Robert Brašić,et al.  18F-FPEB, a PET Radiopharmaceutical for Quantifying Metabotropic Glutamate 5 Receptors: A First-in-Human Study of Radiochemical Safety, Biokinetics, and Radiation Dosimetry , 2013, The Journal of Nuclear Medicine.

[24]  E. Berry-Kravis,et al.  Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome , 2012, International journal of pediatrics.

[25]  M. Bear,et al.  Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice , 2012, Neuron.

[26]  Luis F. Jacome,et al.  Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: Possible implications for the pharmacotherapy of autism spectrum disorders , 2011, Brain Research Bulletin.

[27]  P. Hagerman,et al.  FMR1 premutation and full mutation molecular mechanisms related to autism , 2011, Journal of Neurodevelopmental Disorders.

[28]  D. Hessl,et al.  Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization , 2010, Journal of Neurodevelopmental Disorders.

[29]  L. S. MacLeod,et al.  A comparative study of the performance of individuals with fragile X syndrome and Fmr1 knockout mice on Hebb‐Williams mazes , 2010, Genes, brain, and behavior.

[30]  D. Nguyen,et al.  A pilot open label, single dose trial of fenobam in adults with fragile X syndrome , 2009, Journal of Medical Genetics.

[31]  André J. W. van der Kouwe,et al.  Brain morphometry with multiecho MPRAGE , 2008, NeuroImage.

[32]  S. Rivera,et al.  The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments , 2008 .

[33]  Kiralee M. Hayashi,et al.  Neuroanatomy of fragile X syndrome is associated with aberrant behavior and the fragile X mental retardation protein (FMRP) , 2008, Annals of neurology.

[34]  Mark F. Bear,et al.  Correction of Fragile X Syndrome in Mice , 2007, Neuron.

[35]  A. Brownell,et al.  Synthesis and preliminary biological evaluation of 3‐[18F]fluoro‐5‐(2‐pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5 , 2007, Synapse.

[36]  Brett Connolly,et al.  Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. , 2007, Nuclear medicine and biology.

[37]  Matthew K Belmonte,et al.  Fragile X syndrome and autism at the intersection of genetic and neural networks , 2006, Nature Neuroscience.

[38]  Y. Benjamini,et al.  Adaptive linear step-up procedures that control the false discovery rate , 2006 .

[39]  R. Paylor,et al.  Altered anxiety‐related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome , 2005, Genes, brain, and behavior.

[40]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[41]  Danuta Z Loesch,et al.  Phenotypic variation and FMRP levels in fragile X. , 2004, Mental retardation and developmental disabilities research reviews.

[42]  Jeih-San Liow,et al.  Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  Robert B. Innis,et al.  Strategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[44]  Mark F. Bear,et al.  Altered synaptic plasticity in a mouse model of fragile X mental retardation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  V Menon,et al.  Functional neuroanatomy of visuospatial working memory in fragile X syndrome: relation to behavioral and molecular measures. , 2001, The American journal of psychiatry.

[46]  Stephen M. Smith,et al.  A global optimisation method for robust affine registration of brain images , 2001, Medical Image Anal..

[47]  I. Weiler,et al.  Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Sutcliffe,et al.  Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome , 1991, Cell.

[49]  Marc E. Seaman,et al.  Proceedings of the World Molecular Imaging Congress 2015, Honolulu, Hawaii, September 2-5, 2015: Late-Breaking Abstracts , 2016, Molecular Imaging and Biology.

[50]  R. Paylor,et al.  Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome , 2011, Psychopharmacology.

[51]  Allan L Reiss,et al.  Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies. , 2009, Developmental disabilities research reviews.

[52]  W. Kaufmann,et al.  Autism in Genetic Intellectual Disability , 2008 .